BIOALLIANCE PHARMA
BIOALLIANCE PHARMA operates in Diversified Metals & Mining.
BIOALLIANCE PHARMA (C4X) - Total Assets
Latest total assets as of December 2023: €35.27 Million EUR
Based on the latest financial reports, BIOALLIANCE PHARMA (C4X) holds total assets worth €35.27 Million EUR as of December 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BIOALLIANCE PHARMA - Total Assets Trend (2016–2023)
This chart illustrates how BIOALLIANCE PHARMA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BIOALLIANCE PHARMA - Asset Composition Analysis
Current Asset Composition (December 2023)
BIOALLIANCE PHARMA's total assets of €35.27 Million consist of 36.8% current assets and 63.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 19.3% |
| Accounts Receivable | €1.89 Million | 5.4% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.47 Million | 7.0% |
| Goodwill | €18.06 Million | 51.2% |
Asset Composition Trend (2016–2023)
This chart illustrates how BIOALLIANCE PHARMA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BIOALLIANCE PHARMA's current assets represent 36.8% of total assets in 2023, an increase from 29.5% in 2016.
- Cash Position: Cash and equivalents constituted 19.3% of total assets in 2023, up from 19.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 58.0% of total assets, a decrease from 69.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 51.2% of total assets.
BIOALLIANCE PHARMA Competitors by Total Assets
Key competitors of BIOALLIANCE PHARMA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
2H0
F:2H0
|
Germany | €15.27 Million |
BIOALLIANCE PHARMA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BIOALLIANCE PHARMA generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BIOALLIANCE PHARMA is currently not profitable relative to its asset base.
BIOALLIANCE PHARMA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.17 | 2.88 | 1.71 |
| Quick Ratio | 1.17 | 2.88 | 1.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.86 Million | € 13.43 Million | € 5.57 Million |
BIOALLIANCE PHARMA - Advanced Valuation Insights
This section examines the relationship between BIOALLIANCE PHARMA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -18.1% |
| Total Assets | €35.27 Million |
| Market Capitalization | $1.35K USD |
Valuation Analysis
Below Book Valuation: The market values BIOALLIANCE PHARMA's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BIOALLIANCE PHARMA's assets decreased by 18.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BIOALLIANCE PHARMA (2016–2023)
The table below shows the annual total assets of BIOALLIANCE PHARMA from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €35.27 Million | -18.13% |
| 2022-12-31 | €43.09 Million | -18.80% |
| 2021-12-31 | €53.06 Million | +14.10% |
| 2020-12-31 | €46.51 Million | +23.59% |
| 2019-12-31 | €37.63 Million | -40.51% |
| 2018-12-31 | €63.25 Million | -18.99% |
| 2017-12-31 | €78.07 Million | -37.59% |
| 2016-12-31 | €125.10 Million | -- |